Who to call at Ligand Pharmaceuticals Incorporated, and when
Fundz watches for the moments Ligand Pharmaceuticals Incorporated starts buying, and tells you who to reach.
- An alert the day Ligand Pharmaceuticals Incorporated raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Ligand Pharmaceuticals Incorporated, from your own LinkedIn network
Ligand Pharmaceuticals Incorporated
The company shared information publicly (Regulation FD). An 8-K is the notice a US public company must file within four business days of a major event.
www.ligand.comAI Executive Summary
AI-powered analysis of 8-K filing content
Ligand Pharmaceuticals acquired royalty and milestone payment rights for Santen Pharmaceutical's Ryjunea from Sydnexis for $23 million upfront, strategically expanding its pharmaceutical royalty portfolio and positioning itself for future milestone-based revenue.
Key Takeaways
Ligand acquired royalty and milestone payment rights to Ryjunea, a Santen Pharmaceutical product, for $23 million upfront
This transaction represents a strategic portfolio expansion focused on pharmaceutical royalties rather than direct product ownership
2 more takeaways
Related Filings (3)
3 more filings from Ligand Pharmaceuticals Incorporated in the last 90 days
Filing Overview
What This Means
Ligand Pharmaceuticals Incorporated filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.